An audit of the role of PONDx in chemotherapy decision-making in the breast MDT
Association of Breast Surgery ePoster Library. Khout H. 05/13/19; 257140; P096
Mr. Hazem Khout
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P096
Topic: Non surgical treatments
Background:The Oncotype Dx recurrence score (RS) was recommended by NICE in 2015 for routine use in clinical practice to aid decision making for adjuvant chemotherapy in patients with oestrogen receptor positive, HER2 negative, node negative breast cancer. We secured access to the test in patients with 1 - 3 positive nodes as part of a decision impact study (PONDx). This audit aims to review the impact of PONDx in a single large breast unit.Method:Data was collected prospectively on all patients with breast cancer who were eligible for the PONDx test. Data was collected from July 2017 to August 2018. This data included age, tumour size, grade, menopausal status, number of involved lymph nodes and the RS. Estimation of chemotherapy benefit was calculated using PREDICT. Cut offs of 3% and 5% respectively were used to identify those patients traditionally having a discussion of, or recommendation for, first or second line chemotherapy. Results: 36 patients were available for analysis. RS ranged from 1 - 28. Based on PREDICT 9 patients would have had chemotherapy discussed with them and a further 7 would have had chemotherapy recommended. In this series only 7 patients received chemotherapy (RS 15 - 22). The commonest regime was FEC-T. There were no high RS.Conclusion:PONDx RS is a valuable addition to the MDT discussion. Chemotherapy can be avoided in patients with low and intermediate RS who would normally be recommended chemotherapy.
Topic: Non surgical treatments
Background:The Oncotype Dx recurrence score (RS) was recommended by NICE in 2015 for routine use in clinical practice to aid decision making for adjuvant chemotherapy in patients with oestrogen receptor positive, HER2 negative, node negative breast cancer. We secured access to the test in patients with 1 - 3 positive nodes as part of a decision impact study (PONDx). This audit aims to review the impact of PONDx in a single large breast unit.Method:Data was collected prospectively on all patients with breast cancer who were eligible for the PONDx test. Data was collected from July 2017 to August 2018. This data included age, tumour size, grade, menopausal status, number of involved lymph nodes and the RS. Estimation of chemotherapy benefit was calculated using PREDICT. Cut offs of 3% and 5% respectively were used to identify those patients traditionally having a discussion of, or recommendation for, first or second line chemotherapy. Results: 36 patients were available for analysis. RS ranged from 1 - 28. Based on PREDICT 9 patients would have had chemotherapy discussed with them and a further 7 would have had chemotherapy recommended. In this series only 7 patients received chemotherapy (RS 15 - 22). The commonest regime was FEC-T. There were no high RS.Conclusion:PONDx RS is a valuable addition to the MDT discussion. Chemotherapy can be avoided in patients with low and intermediate RS who would normally be recommended chemotherapy.
P096
Topic: Non surgical treatments
Background:The Oncotype Dx recurrence score (RS) was recommended by NICE in 2015 for routine use in clinical practice to aid decision making for adjuvant chemotherapy in patients with oestrogen receptor positive, HER2 negative, node negative breast cancer. We secured access to the test in patients with 1 - 3 positive nodes as part of a decision impact study (PONDx). This audit aims to review the impact of PONDx in a single large breast unit.Method:Data was collected prospectively on all patients with breast cancer who were eligible for the PONDx test. Data was collected from July 2017 to August 2018. This data included age, tumour size, grade, menopausal status, number of involved lymph nodes and the RS. Estimation of chemotherapy benefit was calculated using PREDICT. Cut offs of 3% and 5% respectively were used to identify those patients traditionally having a discussion of, or recommendation for, first or second line chemotherapy. Results: 36 patients were available for analysis. RS ranged from 1 - 28. Based on PREDICT 9 patients would have had chemotherapy discussed with them and a further 7 would have had chemotherapy recommended. In this series only 7 patients received chemotherapy (RS 15 - 22). The commonest regime was FEC-T. There were no high RS.Conclusion:PONDx RS is a valuable addition to the MDT discussion. Chemotherapy can be avoided in patients with low and intermediate RS who would normally be recommended chemotherapy.
Topic: Non surgical treatments
Background:The Oncotype Dx recurrence score (RS) was recommended by NICE in 2015 for routine use in clinical practice to aid decision making for adjuvant chemotherapy in patients with oestrogen receptor positive, HER2 negative, node negative breast cancer. We secured access to the test in patients with 1 - 3 positive nodes as part of a decision impact study (PONDx). This audit aims to review the impact of PONDx in a single large breast unit.Method:Data was collected prospectively on all patients with breast cancer who were eligible for the PONDx test. Data was collected from July 2017 to August 2018. This data included age, tumour size, grade, menopausal status, number of involved lymph nodes and the RS. Estimation of chemotherapy benefit was calculated using PREDICT. Cut offs of 3% and 5% respectively were used to identify those patients traditionally having a discussion of, or recommendation for, first or second line chemotherapy. Results: 36 patients were available for analysis. RS ranged from 1 - 28. Based on PREDICT 9 patients would have had chemotherapy discussed with them and a further 7 would have had chemotherapy recommended. In this series only 7 patients received chemotherapy (RS 15 - 22). The commonest regime was FEC-T. There were no high RS.Conclusion:PONDx RS is a valuable addition to the MDT discussion. Chemotherapy can be avoided in patients with low and intermediate RS who would normally be recommended chemotherapy.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}